European review for medical and pharmacological sciences · 2022
Vitamin D supplementation inhibits NF-kß signaling pathway in lean and obese women with PCOS.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ağar M, Güngör K, Güngör N D, Kavrut M, Madenli A A
Аннотация
OBJECTIVE: This study aims at investigating the effect of vitamin D (VD) replacement therapy on serum nuclear factor-kappa β (NF-kβ) levels in both lean and obese women with Polycystic Ovary Syndrome (PCOS).
PATIENTS AND METHODS: 50 women with PCOS with VD levels lower than 20 ng/mL were included in the study. Participants were equally divided into two groups, as lean and overweight/obese PCOS, according to their body mass index (BMI) values. Patients in both groups received 2000 IU/day oral VD replacement for two months. Serum NF-kβ, VD, demographic and hormonal values of the patients were recorded before and after VD replacement therapy.
RESULTS: Serum insulin and homeostatic model assessment (HOMA-IR) values of overweight/obese women with PCOS were significantly higher than lean women with PCOS. Pre-replacement NF-kβ levels were found to be significantly higher in the overweight/obese PCOS group (3.22 ± 1.09 ng/mL) than in the lean PCOS group (1.22 ± 0.43 ng/mL) (p < 0.03). Serum NF-kβ levels of the patients in the overweight/obese group (1.10 ± 0.30 ng/mL) and the lean group (0.83 ± 0.10 ng/mL) decreased significantly after VD replacement. No significant difference was found between the groups in terms of HOMA-IR, insulin, and total testosterone levels at the end of VD replacement therapy.
CONCLUSIONS: VD replacement therapy contributes to the improvement of subfertility and metabolic imbalance by reducing serum NF-kβ levels in both lean and obese women with PCOS.
PATIENTS AND METHODS: 50 women with PCOS with VD levels lower than 20 ng/mL were included in the study. Participants were equally divided into two groups, as lean and overweight/obese PCOS, according to their body mass index (BMI) values. Patients in both groups received 2000 IU/day oral VD replacement for two months. Serum NF-kβ, VD, demographic and hormonal values of the patients were recorded before and after VD replacement therapy.
RESULTS: Serum insulin and homeostatic model assessment (HOMA-IR) values of overweight/obese women with PCOS were significantly higher than lean women with PCOS. Pre-replacement NF-kβ levels were found to be significantly higher in the overweight/obese PCOS group (3.22 ± 1.09 ng/mL) than in the lean PCOS group (1.22 ± 0.43 ng/mL) (p < 0.03). Serum NF-kβ levels of the patients in the overweight/obese group (1.10 ± 0.30 ng/mL) and the lean group (0.83 ± 0.10 ng/mL) decreased significantly after VD replacement. No significant difference was found between the groups in terms of HOMA-IR, insulin, and total testosterone levels at the end of VD replacement therapy.
CONCLUSIONS: VD replacement therapy contributes to the improvement of subfertility and metabolic imbalance by reducing serum NF-kβ levels in both lean and obese women with PCOS.